Tolcapone Improves Cognition and Cortical Information Processing in Normal Human Subjects
The DOI matches its Crossref record; 38 of the 39 references it cites were found in a registry or an index.
Abstract
Prefrontal cortical dopamine (DA) regulates various executive cognitive functions, including attention and working memory. Efforts to enhance prefrontal-related cognition, which have focused on catecholaminergic stimulant drugs, have been unsatisfactory. Recently, the demonstration that a functional polymorphism in the catecholamine-O-methyltransferase (COMT) gene impacts prefrontal cognition raises the possibility of a novel pharmacological approach for the treatment of prefrontal lobe executive dysfunction. To explore in a proof of concept study the effects of tolcapone, a CNS penetrant specific COMT inhibitor, we performed a randomized, double blind, placebo controlled, and crossover design of this drug in normal subjects stratified by COMT (val158met) genotype. COMT enzyme activity was determined in peripheral blood. Forty-seven normal volunteers with no family history of psychiatric disorders underwent neuropsychological testing and 34 of those subjects underwent physiological measurement of prefrontal information processing assessed by blood oxygen level-dependent functional magnetic resonance imaging (fMRI). We found significant drug effects on measures of executive function and verbal episodic memory and a significant drug by genotype interaction on the latter, such that individuals with val/val genotypes improved, whereas individuals with met/met genotypes worsened on tolcapone. fMRI revealed a significant tolcapone-induced improvement in the efficiency of information processing in prefrontal cortex during a working memory test. This study demonstrates enhancement of prefrontal cortical function in normal human subjects with a nonstimulant drug having COMT inhibitory activity. Our results are consistent with data from animal studies and from computational models of the effects of selective enhancement of DA signaling in the prefrontal cortex.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“increasing dopamine activity in the mPFC improved set-shifting in humans (Apud et al 2007).”
From Prefrontal cortex executive processes affected by stress in health and disease (2018) · cites this paper as Apud et al 2007
In the citing paper
“For example, increasing DA levels in individuals who have high baseline DA levels impairs cognitive performance, (perhaps pushing them over the peak of the inverted U curve) whereas improvements are noted in individuals with lower baseline levels (pushing them closer to the apex of the curve) (Mattay, Goldberg et al. 2003; Apud, Mattay et al. 2007; Cools, Frank et al. 2009).”
From Developmental imaging genetics: Linking dopamine function to adolescent behavior (2014) · cites this paper as Apud, Mattay et al. 2007
In the citing paper
“Furthermore, increasing DA levels interacts with the COMT val158met SNP consistent with the putative inverted U model with met individuals demonstrating diminished cortical efficiency during tasks of cognitive control and val individuals demonstrating improvements (Mattay, Goldberg et al. 2003; Apud, Mattay et al. 2007).”
From Developmental imaging genetics: Linking dopamine function to adolescent behavior (2014) · cites this paper as Apud, Mattay et al. 2007
Citations
Cites
Effect of COMT Val 108/158 Met genotype on frontal lobe function and risk for schizophrenia
Egan, M. F., Goldberg, T. E., Kolachana, B. S., Callicott, J. H., Mazzanti, C. M., Straub, R. E., Goldman, D., & Weinberger, D. R. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.111134598 · Cited by 2,381 · cited 6×
“This genetic effect has been demonstrated in humans for performance on a variety of cognitive tests, such as working memory and executive function (Egan et al, 2001; Ho et al, 2005) as well as prefrontal physiology as assessed by functional magnetic resonance imaging (fMRI) (Egan et al, 2001;…”
BackgroundMethodInfluentialSelf-citationChen, J., Lipska, B. K., Halim, N., Ma, Q. D., Matsumoto, M., Melhem, S., Kolachana, B. S., Hyde, T. M., Herman, M. M., Apud, J., et al. (2004) · The American Journal of Human Genetics · doi:10.1086/425589 · Cited by 1,675 · cited 3×
“COMT val158met (rs4680 G to A) genotyping was determined using Taqman 50-exonuclease allelic discrimination assay (Applied Biosystems, Foster City, CA) as described elsewhere (Chen et al, 2004).”
BackgroundMethodSelf-citationThe principal features and mechanisms of dopamine modulation in the prefrontal cortex
Seamans, J. K., & Yang, C. R. (2004) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2004.05.006 · Cited by 1,592 · cited 2×
“There are also reports that COMT genotype affects function on declarative memory tests referable to processing in temporal lobe structures implicated in long-term memory (de Frias et al, 2004) Converging evidence from electrophysiological studies in experimental animals indicates that DA focuses and stabilizes prefron…”
BackgroundMendelian Proportions in a Mixed Population
Hardy, G. H. (1908) · Science · doi:10.1126/science.28.706.49 · Cited by 1,339
Männistö, P. T., & Kaakkola, S. (1999) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01423-6 · Cited by 1,068 · cited 2×
“0 h after administration of tolcapone and maximum inhibition of COMT activity in red blood cells is achieved between 1 and 4 h following administration of the drug (Jorga et al, 1999; Jorga, 1998; Mannisto and Kaakkola, 1999).”
BackgroundInfluentialMattay, V. S., Goldberg, T. E., Fera, F., Hariri, A. R., Tessitore, A., Egan, M. F., Kolachana, B., Callicott, J. H., & Weinberger, D. R. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0931309100 · Cited by 893 · cited 9×
“In fact, the effects of amphetamine on prefrontal efficiency measured with fMRI (Mattay et al, 2003) were more noticeable in val/val individuals, a group with putatively higher COMT activity in the frontal cortex and, hence, relatively lower DLFPC synaptic DA concentrations.”
BackgroundMethodInfluentialSelf-citationGogos, J. A., Morgan, M., Luine, V., Santha, M., Ogawa, S., Pfaff, D., & Karayiorgou, M. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.17.9991 · Cited by 864 · cited 4×
“…release or metabolism, studies of COMT knock-out mice and of COMT inhibitors in rodents indicate that COMT has little impact on norepinephrine flux in prefrontal cortex, perhaps because of the abundance of functional norepinephrine transporters (Gogos et al, 1998; Tunbridge et al, 2004).”
BackgroundResultInfluentialAuditory Working Memory and Wisconsin Card Sorting Test Performance in Schizophrenia
Gold, J. M. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830140071013 · Cited by 819 · cited 2×
“…to COMT genotype (notably, N Back, CPT, verbal memory, ID/ED), engage prefrontal cortical processes, and/or demonstrate a response to psychostimulant medication (notably verbal fluency, trail making and letter number span) (D’Esposito et al, 2000; Gold et al, 1997; Gourovitch et al, 2000).”
BackgroundPrefrontal cortical contributions to working memory: evidence from event-related fMRI studies
D'Esposito, M., Postle, B. R., & Rypma, B. (2000) · Experimental Brain Research · doi:10.1007/s002210000395 · Cited by 794 · cited 2×
“…to COMT genotype (notably, N Back, CPT, verbal memory, ID/ED), engage prefrontal cortical processes, and/or demonstrate a response to psychostimulant medication (notably verbal fluency, trail making and letter number span) (D’Esposito et al, 2000; Gold et al, 1997; Gourovitch et al, 2000).”
BackgroundPrefrontal neurons and the genetics of schizophrenia
Weinberger, D. R., Egan, M. F., Bertolino, A., Callicott, J. H., Mattay, V. S., Lipska, B. K., Berman, K. F., & Goldberg, T. E. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01252-5 · Cited by 741 · cited 1×
“This drug by genotype effect is consistent with relatively lower prefrontal cortical DA signaling in these subjects and presumed benefit of enhanced prefrontal DA in this context (Mattay et al, 2003; Weinberger et al, 2001).”
BackgroundSelf-citation
Research works printed but not linked: 3
- McNair D, Lorr M (1981). ITS Manual for the Profile of Mood States. Multi-health System, Inc.: San Diego, CA.
- Weinberg W (1908). ber den Nachweis der Vererbung beim Menschen. Jahresh Ver Vaterl Naturk Württemb 64: 368–382.
- Zurcher G, Dingemanse J, Da Prada M (1991). Ro-40-7592, A Potent Inhibitor of Extracerebral and Brain Catechol-O-methyltransferase: Preclinical and Clinical Findings. John Libbey SRL: Rome.
Cited by
Inverted-U–Shaped Dopamine Actions on Human Working Memory and Cognitive Control
Cools, R., & D'Esposito, M. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.03.028 · Cited by 1,673
The Neuropsychopharmacology of Fronto-Executive Function: Monoaminergic Modulation
Robbins, T. W., & Arnsten, A. F. T. (2009) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.051508.135535 · Cited by 957
“…role of DA in intradimensional set shifting in primates has been supported by a recent pharmacological study of the effects of the COMT inhibitor tolcapone in humans: This drug, which may enhance PFC DA function , improved intradimensional shift performance in volunteers (Apud et al. 2007).”
BackgroundDurstewitz, D., & Seamans, J. K. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.05.015 · Cited by 586
Miyamoto, S., Miyake, N., Jarskog, L. F., Fleischhacker, W. W., & Lieberman, J. A. (2012) · Molecular Psychiatry · doi:10.1038/mp.2012.47 · Cited by 573
Cognitive Control Deficits in Schizophrenia: Mechanisms and Meaning
Lesh, T. A., Niendam, T. A., Minzenberg, M. J., & Carter, C. S. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2010.156 · Cited by 506
“In addition, a small study found atomoxetine to improve working memory-related PFC activity in schizophrenia (Friedman et al, 2008), and inhibition of COMT with tolcapone improves cortical activity and working memory performance in healthy adults, dependent on COMT genotype (Apud et al, 2007).”
BackgroundLogue, S. F., & Gould, T. J. (2014) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2013.08.007 · Cited by 477
“Increasing synaptic DA by inhibiting catecholamine-omethyl-transferase (COMT), the enzyme responsible for degradation of DA, improved set-shifting in humans (Apud et al. 2007) but failed to improve set-shifting in rats (Tunbridge et al. 2004).”
BackgroundNeural substrates of pleiotropic action of genetic variation in COMT: a meta-analysis
Mier, D., Kirsch, P., & Meyer-Lindenberg, A. (2010) · Molecular Psychiatry · doi:10.1038/mp.2009.36 · Cited by 464
Variation in dopamine genes influences responsivity of the human reward system
Dreher, J.-C., Kohn, P., Kolachana, B., Weinberger, D. R., & Berman, K. F. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805517106 · Cited by 376
“Because no equivalent polymorphism of the human COMT gene has been found in any other species examined to date (44), the met variant appears to be specific to humans.”
BackgroundSelf-citationRole of dopamine in the motivational and cognitive control of behavior
Cools, R. (2008) · The Neuroscientist · doi:10.1177/1073858408317009 · Cited by 352
Estrogen Shapes Dopamine-Dependent Cognitive Processes: Implications for Women's Health
Jacobs, E., & D'Esposito, M. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.6394-10.2011 · Cited by 342
“The COMT enzyme activity assay is based on the organic solvent extraction method that separates the radioactive product; the methylated catechol; and the free radioactive coenzyme, 3H-S-adenosyl-methionine, as described previously (Apud et al., 2007).”
From maps to mechanisms through neuroimaging of schizophrenia
Meyer-Lindenberg, A. (2010) · Nature · doi:10.1038/nature09569 · Cited by 318
Young, J. W., Powell, S. B., Risbrough, V., Marston, H. M., & Geyer, M. A. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.02.004 · Cited by 298
Using genetic data in cognitive neuroscience: from growing pains to genuine insights
Green, A. E., Munafò, M. R., DeYoung, C. G., Fossella, J. A., Fan, J., & Gray, J. R. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2461 · Cited by 279
Luerding, R., Weigand, T., Bogdahn, U., & Schmidt-Wilcke, T. (2008) · Brain · doi:10.1093/brain/awn229 · Cited by 251
Tan, H.-Y., Callicott, J. H., & Weinberger, D. R. (2007) · Cerebral Cortex · doi:10.1093/cercor/bhm069 · Cited by 266
“This might be analogous to the recruitment of extraneous neural activity in the early phases of a variety of learning paradigms, when the optimal cognitive strategy has not been arrived at, and when the task might conceivably be found to be more difficult (Andreasen et al. 1995; Shadmehr and…”
BackgroundSelf-citationMolecular Targets for Treating Cognitive Dysfunction in Schizophrenia
Gray, J. A., & Roth, B. L. (2007) · Schizophrenia Bulletin · doi:10.1093/schbul/sbm074 · Cited by 225
“Interestingly, a recent proof-of-concept experiment in normal human subjects treated with tolcapone demonstrated significant improvements on measures of executive function and verbal episodic memory in individuals with a Val/Val genotype but a diminished performance of individuals with the Met/Met genotype.(196) Thus,…”
BackgroundHall, K. T., Lembo, A. J., Kirsch, I., Ziogas, D. C., Douaiher, J., Jensen, K. B., Conboy, L. A., Kelley, J. M., Kokkotou, E., & Kaptchuk, T. J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0048135 · Cited by 205
“Four other placebo-controlled studies designed to examine the effects of tolcapone, a COMT inhibitor, looked at the association between COMT val158met genotype, cognition and information processing [42,43,44,45].”
BackgroundThe treatment of cognitive impairment in schizophrenia
Goff, D. C., Hill, M., & Barch, D. (2011) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2010.11.009 · Cited by 194
Tan, H.-Y., Nicodemus, K. K., Chen, Q., Li, Z., Brooke, J. K., Honea, R., Kolachana, B. S., Straub, R. E., Meyer-Lindenberg, A., Sei, Y., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34725 · Cited by 194
“, the relative “inefficiency” of cortical engagement during the N-back task, defined as the increased magnitude of the response in the context of fixed task performance, has been linked to reduced cortical DA function in normal subjects (26, 28, 30, 47) and in patients with Parkinson disease (48, 49).”
BackgroundSelf-citationCatechol-O-Methyltransferase Inhibitors in Parkinson’s Disease
Müller, T. (2015) · Drugs · doi:10.1007/s40265-014-0343-0 · Cited by 190
“From the pharmacological point of view, tolcapone appears to be more efficacious than entacapone, with higher inhibition of COMT activity, central action and a longer duration of action after oral administration to rats and humans [73, 74, 114].”
BackgroundAssessing cognitive function in clinical trials of schizophrenia
Barnett, J. H., Robbins, T. W., Leeson, V. C., Sahakian, B. J., Joyce, E. M., & Blackwell, A. D. (2010) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2010.01.012 · Cited by 174
Prefrontal cortex executive processes affected by stress in health and disease
Girotti, M., Adler, S. M., Bulin, S. E., Fucich, E. A., Paredes, D., & Morilak, D. A. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.07.004 · Cited by 176
Tan, H.-Y., Chen, Q., Sust, S., Buckholtz, J. W., Meyers, J. D., Egan, M. F., Mattay, V. S., Meyer-Lindenberg, A., Weinberger, D. R., & Callicott, J. H. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0610125104 · Cited by 173
Self-citationEffects of chronic stress on cognitive function – From neurobiology to intervention
Girotti, M., Bulin, S. E., & Carreno, F. R. (2024) · Neurobiology of Stress · doi:10.1016/j.ynstr.2024.100670 · Cited by 210
“Thus, in monkeys, depletion of dopamine in the mPFC using 6-OHDA produced deficits in set-shifting (Crofts et al., 2001; Robbins and Roberts 2007) and in humans increasing dopamine activity in the mPFC improved set-shifting (Apud et al., 2007).”
Uddin, M. S., Rahman, M. M., Jakaria, M., Rahman, M. S., Hossain, M. S., Islam, A., Ahmed, M., Mathew, B., Omar, U. M., Barreto, G. E., et al. (2020) · Molecular Neurobiology · doi:10.1007/s12035-020-01911-8 · Cited by 156
Farrell, S. M., Tunbridge, E., Braeutigam, S., & Harrison, P. J. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.12.023 · Cited by 145
Dopamine, Corticostriatal Connectivity, and Intertemporal Choice
Kayser, A. S., Allen, D. C., Navarro-Cebrian, A., Mitchell, J. M., & Fields, H. L. (2012) · Journal of Neuroscience · doi:10.1523/jneurosci.1180-12.2012 · Cited by 146
“Similarly, in a study of executive function, Apud et al. (2007) found that subjects with a more active form of COMT showed greater improvements on tests of set shifting and verbal episodic memory when administered tolcapone.”
BackgroundGiakoumaki, S. G., Roussos, P., & Bitsios, P. (2008) · Neuropsychopharmacology · doi:10.1038/npp.2008.82 · Cited by 151
Diaz-Asper, C. M., Goldberg, T. E., Kolachana, B. S., Straub, R. E., Egan, M. F., & Weinberger, D. R. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.03.031 · Cited by 146
Self-citationMillan, M. J., Goodwin, G. M., Meyer-Lindenberg, A., & Ove Ögren, S. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.01.016 · Cited by 132
“This is what has been observed upon administration of the brain tissuepenetrant COMT inhibitor tolcapone (Apud et al., 2007).”
BackgroundZandbelt, B. B., Gladwin, T. E., Raemaekers, M. A. H., van Buuren, M., Neggers, S. F. W., Kahn, R. S., Ramsey, N. F., & Vink, M. (2008) · NeuroImage · doi:10.1016/j.neuroimage.2008.04.183 · Cited by 125
“…in the motor cortex of patients recovering from stroke after treatment with fluoxetine (Pariente et al., 2001), in the amygdala following oxytocin administration (Kirsch et al., 2005), and in the prefrontal cortex in response to a catecholamine-O-methyltransferase inhibitor (Apud et al., 2007).”
BackgroundInfluentialCOMT val158met moderation of dopaminergic drug effects on cognitive function: a critical review
Schacht, J. P. (2016) · The Pharmacogenomics Journal · doi:10.1038/tpj.2016.43 · Cited by 107
Grant, J. E., Odlaug, B. L., Chamberlain, S. R., Hampshire, A., Schreiber, L. R. N., & Kim, S. W. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.07.008 · Cited by 110
Tunbridge, E. M., Narajos, M., Harrison, C. H., Beresford, C., Cipriani, A., & Harrison, P. J. (2019) · Biological Psychiatry · doi:10.1016/j.biopsych.2019.05.014 · Cited by 113
“We intended to investigate whether gender influenced COMT functional associations (15), but found only three studies (of enzyme activity) which allowed this issue to be addressed (20-22).”
Inhibitors of MAO-B and COMT: their effects on brain dopamine levels and uses in Parkinson’s disease
Finberg, J. P. M. (2018) · Journal of Neural Transmission · doi:10.1007/s00702-018-1952-7 · Cited by 106
Pharmacological Cognitive Enhancement in Schizophrenia
Harvey, P. D. (2009) · Neuropsychology Review · doi:10.1007/s11065-009-9103-4 · Cited by 106
“Amphetamine has a long history in schizophrenia and has been used for the treatment of many different symptoms despite its reputation as a psychotomimetic and potentiator of relapse ( Angrist et al. 1980 .”
BackgroundRelationship of Striatal Dopamine Synthesis Capacity to Age and Cognition
Braskie, M. N., Wilcox, C. E., Landau, S. M., O’Neil, J. P., Baker, S. L., Madison, C. M., Kluth, J. T., & Jagust, W. J. (2008) · Journal of Neuroscience · doi:10.1523/jneurosci.3729-08.2008 · Cited by 103
“…be modulated by the dopamine system endogenously via genotypes (Egan et al., 2001; Mattay et al., 2003; Blasi et al., 2005; Bertolino et al., 2006; Apud et al., 2007; Caldú et al., 2007; Starr et al., 2007; Zhang et al., 2007; Roussos et al., 2008) or exogenously using pharmaceuticals…”
BackgroundDevelopmental imaging genetics: Linking dopamine function to adolescent behavior
Padmanabhan, A., & Luna, B. (2014) · Brain and Cognition · doi:10.1016/j.bandc.2013.09.011 · Cited by 87
Chen, J., Song, J., Yuan, P., Tian, Q., Ji, Y., Ren-Patterson, R., Liu, G., Sei, Y., & Weinberger, D. R. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.262790 · Cited by 76
Self-citationModulatory Effects of Modafinil on Neural Circuits Regulating Emotion and Cognition
Rasetti, R., Mattay, V. S., Stankevich, B., Skjei, K., Blasi, G., Sambataro, F., Arrillaga-Romany, I. C., Goldberg, T. E., Callicott, J. H., Apud, J. A., et al. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.83 · Cited by 83
“…maintenance, retrieval, or updating), the use of the same paradigm as in previous drug studies permits a comparison of the effect of modafinil with other cognitive-enhancing agents, such as amphetamine and tolcapone, albeit in different participants (Mattay et al, 2003; Apud et al, 2007).”
BackgroundResultSelf-citationApud, J. A., & Weinberger, D. R. (2007) · CNS Drugs · doi:10.2165/00023210-200721070-00002 · Cited by 90
“[166,167] Administration of tolcapone 600 mg/day Effect of COMT Inhibitors on resulted in an approximately 40% reduction in blood Cognitive Function COMT activity.”
BackgroundSelf-citationPrefrontal cognitive systems in schizophrenia : Towards human genetic brain mechanisms
Tan, H.-Y., Callicott, J. H., & Weinberger, D. R. (2009) · Cognitive Neuropsychiatry · doi:10.1080/13546800903091665 · Cited by 83
“Indeed, an increasing number of recent pharmacological and gene-based human studies (Apud et al., 2007; Bertolino et al., 2004, 2006, 2009; Gothelf et al., 2005; McIntosh et al., 2007), including in patients with Parkinson’s disease (Mattay et al.”
BackgroundSelf-citationPrefrontal Dopamine Levels Determine the Balance between Cognitive Stability and Flexibility
Fallon, S. J., Williams-Gray, C. H., Barker, R. A., Owen, A. M., & Hampshire, A. (2013) · Cerebral Cortex · doi:10.1093/cercor/bhs025 · Cited by 75
“that will increase PFC DA levels, has been found to improve ID shifting in val homozygotes but impair ID shifting in met homozygotes (Apud et al. 2007).”
BackgroundEffect of abstinence challenge on brain function and cognition in smokers differs by COMT genotype
Loughead, J., Wileyto, E. P., Valdez, J. N., Sanborn, P., Tang, K., Strasser, A. A., Ruparel, K., Ray, R., Gur, R. C., & Lerman, C. (2009) · Molecular Psychiatry · doi:10.1038/mp.2008.132 · Cited by 79
Psychopathological aspects of dopaminergic gene polymorphisms in adolescence and young adulthood
Nemoda, Z., Szekely, A., & Sasvari-Szekely, M. (2011) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2011.04.002 · Cited by 78
Dopamine Modulates Egalitarian Behavior in Humans
Sáez, I., Zhu, L., Set, E., Kayser, A. S., & Hsu, M. (2015) · Current Biology · doi:10.1016/j.cub.2015.01.071 · Cited by 86
Use of monoamine oxidase inhibitors in chronic neurodegeneration
Riederer, P. F., & Müller, T. H. (2016) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2017.1273901 · Cited by 75
Epistatic interaction between COMT and DTNBP1 modulates prefrontal function in mice and in humans
Papaleo, F., Burdick, M., Callicott, J. H., & Weinberger, D. R. (2013) · Molecular Psychiatry · doi:10.1038/mp.2013.133 · Cited by 80
Self-citationCostas, J., Sanjuán, J., Ramos‐Ríos, R., Paz, E., Agra, S., Ivorra, J. L., Páramo, M., Brenlla, J., & Arrojo, M. (2010) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2010.04.021 · Cited by 87
Roussos, P., Giakoumaki, S. G., & Bitsios, P. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.07.008 · Cited by 77
Dopamine, Locus of Control, and the Exploration-Exploitation Tradeoff
Kayser, A. S., Mitchell, J., Weinstein, D., & Frank, M. J. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2014.193 · Cited by 82
Bevilacqua, L. M., & Goldman, D. A. (2011) · Trends in Cognitive Sciences · doi:10.1016/j.tics.2011.07.009 · Cited by 83
McLean, S. L., Idris, N. F., Woolley, M. L., & Neill, J. C. (2009) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2009.01.009 · Cited by 67
“In keeping with this, inhibitors of catechol-O-methyltransferase (COMT), the primary enzyme responsible for metabolic degradation of dopamine specifically in the medial prefrontal cortex (mPFC), have been shown to improve cortical processing in both humans (Apud et al., 2007) and rats (Tunbridge et al.”
BackgroundLaatikainen, L. M., Sharp, T., Harrison, P. J., & Tunbridge, E. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061839 · Cited by 66
“Studies of the impact of tolcapone on cognitive function in humans have reliably demonstrated interactive effects of drug treatment and Val(158)Met genotype [20,21,22], as would be predicted [13].”
Understanding the schizophrenia prodrome
George, M., Maheshwari, S., Chandran, S., Manohar, S., & Rao, T. S. (2017) · Indian Journal of Psychiatry · doi:10.4103/psychiatry.indianjpsychiatry_464_17 · Cited by 79
“Indian Journal of Psychiatry Volume 59, Issue 4, October-December 2017 508 activity when given at an early stage have improved the socio-occupational functioning in affected individuals.[28]”
Catechol-O-methyltransferase (COMT) influences the connectivity of the prefrontal cortex at rest
Tunbridge, E. M., Farrell, S., Harrison, P. J., & Mackay, C. E. (2012) · NeuroImage · doi:10.1016/j.neuroimage.2012.11.059 · Cited by 72
“Pharmacological COMT inhibition is also beneficial to cognitive function, albeit in a COMT genotype-dependent manner; thus, COMT inhibition has received attention as a therapeutic target for cognitive dysfunction (Apud et al., 2007; Farrell et al., 2012; Giakoumaki et al., 2008).”
Backgroundde Frias, C. M., Marklund, P., Eriksson, E., Larsson, A., Öman, L., Annerbrink, K., Bäckman, L., Nilsson, L.-G., & Nyberg, L. (2010) · Journal of Cognitive Neuroscience · doi:10.1162/jocn.2009.21318 · Cited by 62
Brain white matter structure and COMT gene are linked to second-language learning in adults
Mamiya, P. C., Richards, T. L., Coe, B. P., Eichler, E. E., & Kuhl, P. K. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1606602113 · Cited by 63
“Consistent with this idea, COMT activity measured in whole-blood samples were shown to be highest in individuals with the Val/Val genotype, the intermediate level for Val/Met genotype, and the lowest for the Met/Met genotype (26).”
BackgroundInhibitory Control and Drug Abuse Prevention: From Research to Translation
Bardo, M. T., Fishbein, D. H., & Milich, R. S. (2011) · Springer eBooks · doi:10.1007/978-1-4419-1268-8 · Cited by 70
Chavanon, M.-L., Wacker, J., & Stemmler, G. (2013) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2013.00117 · Cited by 62
“…Gibbs and D’Esposito, 2005, 2006; Frank and O’Reilly, 2006; Wallace et al., 2011), dopaminergic genotypes (Mattay et al., 2003; Kirsch et al., 2006; Apud et al., 2007; Cohen et al., 2007; Roussos et al., 2009; Mueller et al., 2011; van Holstein et al., 2011; Rokem et al., 2012) and personality…”
BackgroundClinical Pharmacokinetics and Pharmacodynamics of Safinamide
Müller, T. H., & Foley, P. B. (2016) · Clinical Pharmacokinetics · doi:10.1007/s40262-016-0449-5 · Cited by 63
“son such psychostimulants possess a greater potential for abuse and tolerance [40].”
BackgroundLapish, C. C., Ahn, S., Evangelista, L., So, K., Seamans, J. K., & Phillips, A. G. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1342-1 · Cited by 63
“On the other hand, tolcapone, like amphetamine, also improved the efficiency of information processing during an N-back working memory task as assessed by the fMRI blood oxygen level-dependent response (Apud et al. 2007; Mattay et al. 2003).”
BackgroundInvolvement of the Ventral Tegmental Area in a Rodent Model of Post-Traumatic Stress Disorder
Corral-Frías, N. S., Lahood, R. P., Edelman-Vogelsang, K. E., French, E. D., & Fellous, J. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2012.189 · Cited by 63
Braskie, M. N., Landau, S. M., Wilcox, C. E., Taylor, S. D., O'Neil, J. P., Baker, S. L., Madison, C. M., & Jagust, W. J. (2011) · Human Brain Mapping · doi:10.1002/hbm.21081 · Cited by 58
“DLPFC and precuneus are both known to have reciprocal circuit connectivity with dorsal caudate (DCA) [Alexander et al., 1986; Schmahmann and Pandya, 1990].”
BackgroundInfluentialSabb, F. W., Burggren, A. C., Higier, R. G., Fox, J., He, J., Parker, D. S., Poldrack, R. A., Chu, W., Cannon, T. D., Freimer, N. B., et al. (2009) · Neuroscience · doi:10.1016/j.neuroscience.2009.05.013 · Cited by 58
“Two of these studies report no effect of the val158met genotype on verbal episodic memory (Apud et al., 2007), or logical memory and paired associate word learning (Strauss et al.”
BackgroundThe dopamine augmenter L-DOPA does not affect positive mood in healthy human volunteers.
Liggins, J., Pihl, R. O., Benkelfat, C., & Leyton, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0028370 · Cited by 58
“day 1 [112] 47 POMS 0”
Warneke, W., Klaus, S., Fink, H., Langley‐Evans, S. C., & Voigt, J. (2013) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2013.11.016 · Cited by 58
Innovative mechanisms of action for pharmaceutical cognitive enhancement: A systematic review
Fond, G. B., Micoulaud‐Franchi, J., Brunel, L., Macgregor, A., Miot, S., Lopez, R., Richieri, R. M., Abbar, M., Lançon, C., & Repantis, D. (2015) · Psychiatry Research · doi:10.1016/j.psychres.2015.07.006 · Cited by 59
“Tolcapone (200 mg single dose) is known to significantly improve executive function and verbal episodic memory performance in healthy adults (Apud et al., 2007; Roussos et al., 2009).”
BackgroundKaakkola, S. (2010) · International review of neurobiology · doi:10.1016/b978-0-12-381326-8.00009-0 · Cited by 58
COMT as a Drug Target for Cognitive Functions and Dysfunctions
Scheggia, D., Sannino, S., Scattoni, M. L., & Papaleo, F. (2012) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152712800672481 · Cited by 57
Executive functions and prefrontal cortex: a matter of persistence?
Ball, G., Stokes, P. R., Rhodes, R. A., Bose, S. K., Rezek, I., Wink, A.-M., Lord, L.-D., Mehta, M. A., Grasby, P. M., & Turkheimer, F. E. (2011) · Frontiers in Systems Neuroscience · doi:10.3389/fnsys.2011.00003 · Cited by 50
“Indeed, performance in both the n-back and Tower of London tasks is sensitive to endogenous dopamine levels (Mehta et al., 2005; Reeves et al., 2005; Apud et al., 2007).”
Differential optimal dopamine levels for set-shifting and working memory in Parkinson's disease
Fallon, S. J., Smulders, K., Esselink, R. A. J., van de Warrenburg, B. P. C., Bloem, B. R., & Cools, R. (2015) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2015.07.031 · Cited by 50
“Moreover, the COMT polymorphism has been shown to account for individual variability in the response to pharmacological manipulations that alter dopamine (Apud et al., 2007; Farrell et al., 2012; Kelm and Boettiger, 2013; Mattay et al., 2003).”
Biomarkers for drug development in early psychosis: Current issues and promising directions
GOFF, D. C., Romero, K., Paul, J., Pérez-Rodríguez, M. M., CRANDALL, D. T., & Potkin, S. G. (2016) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2016.01.009 · Cited by 52
“, tolcapone) in Val158Val COMT polymorphism subjects (Apud et al., 2007).”
Motivational Influences on Memory
Murty, V. P., & Dickerson, K. C. (2016) · Advances in motivation and achievement · doi:10.1108/s0749-742320160000019019 · Cited by 56
“On the whole, these studies have shown that dopaminergic agonists improve delayed recall and recognition (or have produced null effects) (Apud et al., 2006; Eckart, Fuentemilla, Bauch, & Bunzeck, 2014; Linssen, Vuurman, Sambeth, & Riedel, 2011; Murphy, Henry, & Weingartner, 1972; Rammsayer,…”
Green, A. E., Kraemer, D. J. M., DeYoung, C. G., Fossella, J., & Gray, J. R. (2012) · Cerebral Cortex · doi:10.1093/cercor/bhs035 · Cited by 52
“Decreased IFG recruitment in Met carriers may be explainable in terms of the dopamine signal-to-noise hypothesis (Winterer and Weinberger 2004; Bertolino et al. 2006; Savitz et al. 2006; Winterer et al. 2006; Apud et al. 2007).”
BackgroundMethodInfluentialWightman, E. L., Jackson, P. A., Forster, J., Khan, J., Wiebe, J. C., Gericke, N., & Kennedy, D. O. (2020) · Nutrients · doi:10.3390/nu12082194 · Cited by 45
“COMT’s catabolic pathway is most prevalent in brain tissue with low concentrations of catecholamine reuptake transporters, and therefore COMT inhibition predominantly affects dopaminergic function in the prefrontal cortex and hippocampus [58], potentially leading to improved working memory, selective attention, and ex…”
BackgroundDopamine Modulation of the Prefrontal Cortex and Cognitive Function
Seamans, J. K., & Robbins, T. W. (2010) · The Dopamine Receptors · doi:10.1007/978-1-60327-333-6_14 · Cited by 39
“executive function when given a COMT inhibitor (Tolcapone) or amphetamine, whereas the Met/Met individuals got less efficient, consistent with moving them off the optimal point of the inverted-U curve (3-back task in [120, 121]).”
BackgroundSmith, G. S., Gunning‐Dixon, F. M., Lotrich, F. E., Taylor, W. D., & Evans, J. D. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301333 · Cited by 48
“…related to a particular behavior and activation response and evaluating a medication targeted at the particular mechanism is best evidenced by the evaluating of the COMT inhibitor tolcopone for augmenting working memory and attentional control processes in normal subjects (Apud et al, 2006).”
BackgroundCatechol-O-methyltransferase polymorphisms and some implications for cognitive therapeutics
Diaz-Asper, C. M., Weinberger, D. R., & Goldberg, T. E. (2006) · NeuroRx · doi:10.1016/j.nurx.2005.12.010 · Cited by 50
Self-citationCOMT Val158Met and cognition: main effects and interaction with educational attainment
Enoch, M., Waheed, J., Harris, C. R., Albaugh, B., & Goldman, D. A. (2008) · Genes Brain & Behavior · doi:10.1111/j.1601-183x.2008.00441.x · Cited by 49
“As discussed in the Introduction, a large body of literature has shown that COMT activity is an important modulator of dorsolateral PFC-dependent cognitive tasks (Apud et al. 2007; Egan et al. 2001; Hariri & Weinberger 2003; Malhotra et al. 2002; Tunbridge et al. 2006).”
BackgroundMeyer, B. M., Huemer, J., Rabl, U., Boubela, R. N., Kalcher, K., Berger, A., Banaschewski, T., Barker, G., Bokde, A., Büchel, C., et al. (2016) · Brain Structure and Function · doi:10.1007/s00429-014-0895-5 · Cited by 39
“…and adults which could be explained by a transposition along the hypothetical inverted U-shaped curve (Apud et al. 2007; Wahlstrom et al. 2010), a notion supported by several pharmacological, imaging, or behavioral reports (Apud et al. 2007; Gothelf et al. 2005, 2013; Mattay et al. 2003).”
BackgroundInfluentialIntermediate or brainless phenotypes for psychiatric research?
Meyer-Lindenberg, A. (2010) · Psychological Medicine · doi:10.1017/s0033291709991929 · Cited by 39
“In the available literature, intermediate phenotypes strategies towards personalized treatment strategies based on genetics (Apud et al. 2007), promising novel drug targets (Huffaker et al.”
BackgroundShilling, P. D., Marie, R. L. S., Shoemaker, J. M., & Swerdlow, N. R. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.10.015 · Cited by 41
Tian, T., Qin, W., Liu, B., Jiang, T., & Yu, C. (2013) · The Journal of Neuroscience · doi:10.1523/jneurosci.2163-13.2013 · Cited by 37
Dopamine, time perception, and future time perspective
Mitchell, J., Weinstein, D., Vega, T. A., & Kayser, A. S. (2018) · Psychopharmacology · doi:10.1007/s00213-018-4971-z · Cited by 41
Riedel, W. J., & Blokland, A. (2015) · Handbook of experimental pharmacology · doi:10.1007/978-3-319-16522-6_7 · Cited by 49
Margetts, G., Kleidonas, S., Zaibi, N. S., Zaibi, M. S., & Edwards, K. D. (2022) · BMC Complementary Medicine and Therapies · doi:10.1186/s12906-022-03605-1 · Cited by 38
COMT genotype and cognitive function: An 8-year longitudinal study in white and black elders
Fiocco, A. J., Lindquist, K. J., Ferrell, R. E., Li, R., Simonsick, E. M., Nalls, M. A., Harris, T. B., & Yaffe, K. S. (2010) · Neurology · doi:10.1212/wnl.0b013e3181d9edba · Cited by 42
Effects of tolcapone and bromocriptine on cognitive stability and flexibility
Cameron, I. G. M., Wallace, D. L., Al-Zughoul, A. B., Kayser, A. S., & D’Esposito, M. (2018) · Psychopharmacology · doi:10.1007/s00213-018-4845-4 · Cited by 36
Robinson, R., Smith, S. M., Wolkenberg, S., Kandebo, M., Yao, L., Gibson, C. R., Harrison, S. T., Polsky-Fisher, S., Barrow, J., Manley, P., et al. (2012) · ACS Chemical Neuroscience · doi:10.1021/cn200109w · Cited by 34
Laatikainen, L. M., Sharp, T., Bannerman, D. M., Harrison, P. J., & Tunbridge, E. M. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112454228 · Cited by 37
“…and delayed spatial win-shift performance (Lapish et al., 2009), and (albeit Val158Met genotypedependent) improvements in cognitive function seen after tolcapone administration in humans (Apud et al., 2007; Farrell rats (closed bar; n=20), compared with those vehicle-treated (open bars; n=20).”
ResultWacker, J., & Gatt, J. M. (2010) · Neuroscience Letters · doi:10.1016/j.neulet.2010.04.071 · Cited by 48
Current Management of the Cognitive Dysfunction in Parkinson’s Disease: How Far Have We Come?
Vale, S. (2008) · Experimental Biology and Medicine · doi:10.3181/0707-mr-193 · Cited by 38
“Apud JA, Mattay V, Chen J, Kolachana BS, Callicott JH, Rasetti R, Alce G, Iudicello JE, Akbar N, Egan MF, Goldberg TE, Weinberger DR. Tolcapone improves cognition and cortical information processing in normal human subjects.”
BackgroundInfluentialCognitive Enhancers (Nootropics). Part 2: Drugs Interacting with Enzymes
Froestl, W., Muhs, A., & Pfeifer, A. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-121537 · Cited by 33
“ing in normal human subjects [1144].”
Neuroethics and public engagement training needed for neuroscientists
Morein‐Zamir, S., & Sahakian, B. J. (2009) · Trends in Cognitive Sciences · doi:10.1016/j.tics.2009.10.007 · Cited by 31
Hayes, J. P., Logue, M. W., Reagan, A., Salat, D. H., Wolf, E. J., Sadeh, N., Spielberg, J. M., Sperbeck, E., Hayes, S. M., McGlinchey, R. E., et al. (2017) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.150339 · Cited by 31
Central nervous system activities of extract Mangifera indica L.
López-Ríos, L., Wiebe, J. C., Vega-Morales, T., & Gericke, N. (2020) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2020.112996 · Cited by 27
Berg, J. W., Mehlman, M. J., Rubin, D. B., & Kodish, E. D. (2009) · Clinical Pediatrics · doi:10.1177/0009922808330457 · Cited by 29
Hall, K. T., Kossowsky, J., Oberlander, T. F., Kaptchuk, T. J., Saul, J. P., Wyller, V. B., Fagermoen, E., Sulheim, D., Gjerstad, J., Winger, A., et al. (2016) · The Pharmacogenomics Journal · doi:10.1038/tpj.2016.53 · Cited by 29
“Furthermore, COMT has also been shown to modify clinical response to both active drugs (4, 9-12) and placebo treatments (13, 14) in randomized clinical trials.”
BackgroundMüller, T. (2017) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2017.1329418 · Cited by 27
Metadata
- Authors
- Apud, J. A., Mattay, V., Chen, J., Kolachana, B. S., Callicott, J. H., Rasetti, R., Alce, G., Iudicello, J. E., Akbar, N., Egan, M. F., Goldberg, T. E., & Weinberger, D. R.
- Affiliations
- National Institutes of Health (US)
- Corresponding author
- Weinberger, Daniel R
- ORCID
- Venue
- Neuropsychopharmacology
- Published
- 2006-10-25
- Volume
- 32
- Issue
- 5
- Pages
- 1011-1020
- ISSN
- 0893-133X (ISSN-L)
- 1740-634X
- OpenAlex
- W2123236884
- Cited by
- 242
- References
- 39
- Citations by year
- 2026: 4 · 2025: 1 · 2024: 9 · 2023: 4 · 2022: 19 · 2021: 9 · 2020: 12 · 2019: 4 · 2018: 7 · 2017: 12 · 2016: 14 · 2015: 13 · 2014: 6 · 2013: 25 · 2012: 18
- FWCI
- 6.29
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Neuropsychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Life Sciences › Neuroscience › Cognitive Neuroscience › Neural and Behavioral Psychology Studies
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- tolcapone, COMT inhibition, COMT Val158Met polymorphism, prefrontal cortex, executive function, working memory, verbal episodic memory, dopamine signaling
- MeSH terms
- Tolcapone, Adult, Benzophenones, Brain Mapping, Catechol O-Methyltransferase, Cognition, Double-Blind Method, Enzyme Inhibitors, Female, Genotype, Humans, Magnetic Resonance Imaging, Male, Memory, Middle Aged, Neuropsychological Tests, Nitrophenols, Placebos, Reference Values, Treatment Outcome, Prefrontal Cortex, Cross-Over Studies, Amino Acid Substitution, Catechol O-Methyltransferase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.